Clinical trials: Psychological Disorders
Schizophrenia
12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
There has been evidence that ziprasidone is efficacious in decreasing the magnitude of both positive and negative symptoms of schizophrenia, and also effective in the treatment of depressive symptoms.
- Trial name
- NCT00159757
- Testing
- ziprazidone
- Where
- 8 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Opioid Users
Abuse Potential Study of PF-00345439
This study will determine the relative abuse potential of intact and chewed PF-00345439 (Oxycodone Extended-Release Capsules) compared to crushed oxycodone HCL immediate release (IR) tablets and placebo administered orally to…
- Trial name
- NCT01986283
- Testing
- Capsule, PF-00345439, oxycodone
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Pain Therapeutics
Schizophrenia, Paranoid, Schizophrenia, Disorganized
Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is also effective in adolescents with…
- Conditions
- Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
- Trial name
- NCT01190254
- Testing
- asenapine 2.5 mg, asenapine 5.0 mg
- Volunteers
- 306 people
- Sponsor
- Organon and Co
Major Depressive Disorder, Treatment Resistant Depression
Open-Label Safety Study of AXS-05 in Subjects With Depression
An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Depression
- Trial name
- NCT04039022
- Testing
- AXS-05 (dextromethorphan and bupropion) oral tablets
- Where
- 51 sites in United States
- Volunteers
- 876 people
- Sponsor
- Axsome Therapeutics, Inc.
Attention Deficit Hyperactivity Disorder
A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).
- Trial name
- NCT00965419
- Testing
- Edivoxetine
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 267 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease
The primary efficacy objective of this study is to test the hypothesis that DBS-f stimulation (ON) will slow cognitive and functional progression of AD, as compared to no stimulation (OFF), by measuring baseline…
- Trial name
- NCT03622905
- Testing
- DBS-f On, DBS Off
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 74 people
- Sponsor
- Functional Neuromodulation Ltd
Schizophrenia
Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital
The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 12 months, in patients diagnosed with schizophrenia who were…
- Trial name
- NCT01193166
- Testing
- paliperidone palmitate, risperidone, olanzapine
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Tourette's Disorder
Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current study is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01418339
- Testing
- Aripiprazole
- Where
- 39 sites in United States, Canada and 4 more
- Volunteers
- 135 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer's Disease
Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy
The study will include a preliminary pharmacokinetics (PK) / safety / tolerability evaluation in healthy elderly subjects followed by the Receptor Occupancy (RO) evaluations in healthy elderly subjects and in Alzheimer's Disease…
- Trial name
- NCT00499200
- Testing
- SRA-444
- Where
- Sweden
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00477672
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 78 sites in United States, Bulgaria and 5 more
- Volunteers
- 298 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Narcolepsy, Sleep Apnea, Obstructive
Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder
The primary objective of this study is to evaluate the safety and tolerability of Armodafinil (CEP-10953) administered on a flexible-dosage regimen of 100 to 250 mg/day for up to 12 months to patients with excessive sleepiness…
- Conditions
- Narcolepsy, Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Shift-Work Sleep Disorder
- Trial name
- NCT00078312
- Testing
- CEP-10953 (Armodafinil)
- Where
- 50 sites in United States, Russia
- Volunteers
- 328 people
- Sponsor
- Cephalon
Generalized Anxiety Disorder
A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).
- Trial name
- NCT00236067
- Testing
- Gabitril
- Where
- 21 sites in United States
- Volunteers
- 440 people
- Sponsor
- Cephalon
Schizophrenia
A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia
The primary objective of the study was to determine the safety of aripiprazole administered long-term in doses ranging from 10 to 30 mg per day as a maintenance therapy in subjects with chronic or first episode of schizophrenia.
- Trial name
- NCT02435836
- Testing
- Aripiprazole
- Volunteers
- 631 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression
The purpose of this study is to evaluate the safety and effectiveness of JNJ-18038683 compared to escitalopram and placebo in patients with moderate to severe depression.
- Trial name
- NCT00566202
- Testing
- Escitalopram, JNJ-18038683
- Where
- 26 sites in United States
- Volunteers
- 67 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Mental Health, Mental Disorders
Personalized, Transdiagnostic Approach to Preventative Mental Health
This study is investigating the self-report adherence and assessment completion rates when presented with a transdiagnostic, partial assessment multiple times a day when compared with a monotopic, complete assessment once a day.
- Conditions
- Mental Health, Mental Disorders, Delivery of Health Care, Self-Assessment
- Trial name
- NCT03946319
- Testing
- Introspect Health
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Introspect Health
Sleep Disorder (Disorder)
US Development and Evaluation Study of a Patch-Based PSG System
The purpose of this study is continue the development and evaluation of the Onera system as well as the procedures and best practices for dispensing, instruction, use and reportability of results.
- Trial name
- NCT06881667
- Testing
- Home PSG Assessment
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Onera BV
Alzheimer's Disease
An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
The goal of this research study is to evaluate, in the open-label extension phase, the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease
- Trial name
- NCT00219232
- Testing
- Rivastigmine Transdermal Patch
- Volunteers
- 868 people
- Sponsor
- Novartis
Schizophrenia
A Repeat Dose Positron Emission Tomography Study With GSK1144814
This study described in the present protocol consists of two parts. Part A is a multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of ascending doses of GSK1144814.
- Trial name
- NK1 NK3 PET (NCT01209039)
- Testing
- GSK1144814
- Where
- 2 sites in United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia, Cognition Disorders
The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients
This study in patients with stable schizophrenia will investigate the effect of nicotine on arousal, cognitive task and social cognition after acute dose administration.
- Trial name
- NCT01186471
- Testing
- A643 (nicotine)
- Volunteers
- 32 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Fatigue, Stress
The U.K. Embryologist Fatigue Study
The purpose of the study is to determine physical and mental health issues of U.K. embryologists related to their occupational characteristics, and how workplace fatigue and burnout may affect their quality of life, cynicism…
- Conditions
- Fatigue, Stress, Burnout, Professional, Musculoskeletal Pain
- Trial name
- FUSE-UK (NCT05708963)
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- TMRW Life Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.